Of 122 ACC tumors evaluated in the ENSAT study, nine genes displayed damaging mutations, homozygous deletions, or high-level amplifications in ≥ 5% of ACCs: ZNRF3, CTNNB1, TP53, CDKN2A, RB1, MEN1, DAXX, MED12, and TERT. The TCGA group analyzed their data via the Cancer Gene Consensus and also noted that NF1 and MLL4 were mutated in more than 5% of the cohort (33, 34). This evidence concerns the gene TP53 and adrenal cortex carcinoma.